Patents by Inventor Abdessamad Debbab

Abdessamad Debbab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140371158
    Abstract: Methods of inhibiting the Hsp90 chaperone pathway including contacting one or more target cells with an effective amount of a naturally occurring beauvericin, a synthetic beauvericin, or a derivative, analog or prodrug, or a pharmacologically active salt thereof to reduce, decrease, or inhibit the Hsp90 chaperone pathway in the cells compared to a control are disclosed. The methods can reduce the viability of the target cells, for example, by increasing apoptosis or pro-apoptotic pathways. In preferred embodiments, the methods reduce or do not increase Hsp70, Hsp24, Hsp40, or HOP expression; reduce or do not increase the heat shock response; reduce or do not increase pro-survival pathways in the cells. Methods of treating diseases such as cancer, inflammatory diseases or disorders, neurodegenerative diseases, and infectious diseases using the disclosed compositions and methods are also disclosed.
    Type: Application
    Filed: June 16, 2014
    Publication date: December 18, 2014
    Inventors: Ahmed Chadli, Abdessamad Debbab, Peter Proksch
  • Publication number: 20120129927
    Abstract: The invention relates to two novel substances, namely (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl altersolanol M) and 8-(4,5,6-trihydroxy-7-methyl-2-methoxy-9,10-dioxo-9H,10H-anthracen-1-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (the atropisomers alterporriol I and J) to their use as anti-infectives and as anti-cancer agents, as well as to methods of producing the same.
    Type: Application
    Filed: May 31, 2010
    Publication date: May 24, 2012
    Applicant: SEALIFE PHARMA GMBH
    Inventors: Alexander Pretsch, Peter Proksch, Abdessamad Debbab
  • Publication number: 20120129949
    Abstract: The present invention relates to the use of the following anthracene derivatives as anti-infectives, preferably against multiply drug resistant pathogens: (2R,3S,10R)-2,3,5,10-tetrahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (tetrahydroaltersolanol B), (1R,2R,3R,4aS,9aR,10R)-1,2,3,5,10-pentahydroxy-7-methoxy-2-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol K), (2R,3R,4R,4aS,9aS,10R)-2,3,4,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol L), 8-(1,7-dihydroxy-6-methyl-3-methoxy-9,10-dioxo-9H,10H-anthracen-2-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracen-9,10-dione (atropisomers alterporriol G and H); as well as (2R,3S,4aS,9aS,10R)-2,3,5,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (8-hydroxytetrahydroaltersolanol B).
    Type: Application
    Filed: May 31, 2010
    Publication date: May 24, 2012
    Applicant: SEALIFE PHARMA GMBH
    Inventors: Alexander Pretsch, Peter Proksch, Abdessamad Debbab